Heterocyclic Compounds

Matches 1 - 50 out of 12,168	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/153053A1	CDK INHIBITOR AND CRYSTAL FORM OF PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF Provided is compound A in a crystal form or a pharmaceutically acceptable salt thereof. The structure of compound A is as shown in formula (I) below. Studies have shown that a free base crystal form A-I, hydrochloride salt crystal form B...
WO/2024/153116A1	KRAS G12D INHIBITORS AND USES THEREOF Provided herein are useful compounds for the inhibition of KRAS mutant, in particular KRAS G12D, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharm...
WO/2024/153248A1	FUSED TRICYCLIC COMPOUND AS KINASE INHIBITOR Provided in the present invention is a class of compounds containing a fused tricyclic structure. Specifically, provided in the present invention is a compound having a structure as shown in formula (I), or an optical isomer, a pharmaceu...
WO/2024/153203A1	INTEGRASE INHIBITOR AND USE THEREOF Disclosed are a compound of Formula I, stereoisomers, pharmaceutically acceptable salts and deuterated compounds thereof and a method for treating, inhibiting and/or preventing a disease or disorder in a subject in need thereof: (I) wher...
WO/2024/153568A1	HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES The present invention relates to heterocycles that are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said heterocycles.
WO/2024/153180A1	HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Disclosed in the present invention are a heterocyclic compound, and a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention are a heterocyclic compound as represented by formula (I), a p...
WO/2024/153028A1	MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF Disclosed in the present invention are a macrocyclic compound, a pharmaceutical composition comprising same, and a use thereof. Specifically, disclosed in the present invention are a compound as represented by formula (I), a pharmaceutic...
WO/2024/153161A1	SUBSTITUTED AMINOPYRIMIDINE MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF The present disclosure relates to substituted aminopyrimidine macrocyclic compounds, a preparation method therefor, and the medical uses thereof. Particularly, the present disclosure relates to substituted aminopyrimidine macrocyclic com...
WO/2024/153119A1	KRAS G12D INHIBITORS AND USES THEREOF Provided are compounds for the inhibition of KRAS mutans, in particular KRAS G12D, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical comp...
WO/2024/148932A1	EGFR C797S MUTATION INHIBITOR AND PHARMACEUTICAL USE THEREOF Provided are an EGFR inhibitor having a structure of formula (I), a pharmaceutical composition thereof, the use thereof as an EGFR inhibitor and the use thereof in the preparation of a drug for treating cancers, tumors or metastatic dise...
WO/2024/151346A1	HETEROARYL FLUOROALKENES AS DGK INHIBITORS The present application provides heteroaryl fluoroalkene compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
WO/2024/149214A1	BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS-12D VIA UBIQUITIN PROTEASOME PATHWAY The present disclosure provides certain tetracyclic derivatives that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing...
WO/2024/150815A1	CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR The problem addressed is to provide a novel compound having cereblon E3 ligase binding ability. Provided is a compound represented by formula (I): [in the formula, the symbols are as described in the specification.], formula (II): [in th...
WO/2024/149349A1	COMPOUND TARGETING POLθ AND USE THEREOF A compound as represented by formula (I), a stereoisomer, a deuterated substance, a solvate, a pharmaceutically acceptable salt or an eutectic crystal thereof, or a pharmaceutical composition containing same, and the use thereof as a com...
WO/2024/146541A1	MACROCYCLIC COMPOUNDS AS USP1 INHIBITORS Disclosed a novel series of macrocyclic compounds of Formula I as USP1 inhibitors and their use for the treatment of diseases associated with USP1 enzyme.
WO/2024/148308A1	NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or deuterated forms thereof, wherein R0 , L and R1 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formu...
WO/2024/146617A1	COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR The present invention relates to a bifunctional compound suitable for degrading (and inhibiting) an androgen receptor. Specifically, the compound contains on one end a moiety that binds to E3 ubiquitin ligase and on the other end a moiet...
WO/2024/146608A1	ELECTRON TRANSPORT MATERIAL, PREPARATION METHOD, AND PEROVSKITE SOLAR CELL DEVICE An electron transport material, a preparation method, and a perovskite solar cell device. The electron transport material is of a fused ring structure formed by using indole as a framework and bridging a benzodiazole compound. According ...
WO/2024/140537A1	USE OF CDK INHIBITOR Provided is the use of a CDK inhibitor compound A in the preparation of an anti-tumor drug, in particular the use in the preparation of a drug for treating CDK4/6 inhibitor-resistant tumors. Also provided is a corresponding treatment met...
WO/2024/141444A1	NEW BENZIMIDAZOLE DERIVATIVES The invention relates to a compound of formula (I) wherein L, A1, R1, R2 and R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
WO/2024/140637A1	OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF The present disclosure relates to a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate or polymorph thereof, and a use thereof. The present disclosure further relates to a pharmaceutical composition comprising the compo...
WO/2024/138486A1	TETRACYCLIC DERIVATIVES AS KRAS INHIBITORS The present disclosure provides certain tetracyclic derivatives that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing...
WO/2024/140678A1	A KETAL PROTECTED INTERMEDIATE FOR SONROTOCLAX AND PREPARATION METHOD THEREOF Disclosed herein are compounds of Formula (I) having protective group of ketal used as intermediates for preparing 2- ( (1H-pyrrolo [2, 3-b] pyridin-5-yl) oxy) -N- ( (4- ( ( ( (1r, 4r) -4-hydroxy-4-methylcyclohexyl) methyl) amino) -3-nit...
WO/2023/196900A9	SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of...
WO/2024/140294A1	ORGANIC COMPOUND AND APPLICATION THEREOF IN OLED DEVICE The present invention belongs to the technical field of organic light-emitting devices (OLEDs). Particularly disclosed is an organic compound represented by formula (I), and also disclosed is an application of the organic compound in an ...
WO/2024/144149A1	HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF The present invention pertains to: a heteroaryl derivative compound having EGFR inhibitory activity; and a pharmaceutical use thereof. This compound, a stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or stereo...
WO/2024/131005A1	ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS The present application belongs to the technical field of organic electroluminescence, and relates to an organic compound, an organic electroluminescent device using same, and an electronic apparatus. The organic compound has a structure...
WO/2024/138052A1	HETEROCYCLES AND USES THEREOF The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, ...
WO/2024/137607A1	THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF The present disclosure relates to compounds of Formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein Ring A, R1, R2, R3, R4, and m are described herein, methods of preparation, methods of treatment, and pharmaceutical c...
WO/2024/133292A1	NOVEL CCR8 ANTAGONISTS The invention relates to novel CCR8 antagonists, based on NS-15 as lead structure, were designed and synthesized. To maintain the hydrogen bond potential, focus was on the isosteric replacements of the amide bond. In addition, isosters o...
WO/2024/137940A1	METHODS OF CONTROLLING PLANT PATHOGENS The present invention is directed to methods of controlling oomycetes comprising applying one or more cervinomycins. The present invention is further directed to methods of controlling particular fungi comprising applying one or more cen...
WO/2024/130341A1	BENZIMIDAZOLE DERIVATIVES FOR THE MODULATION OF STING This disclosure relates to compounds of formula (I), which are modulators of STING. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods of using compounds of formula (I) in the treatment or prev...
WO/2024/133014A1	PHENYLPIPERIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN The present disclosure provides certain phenylpiperidine derivatives of formula (I), and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl -peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferas...
WO/2024/131829A1	CRYSTAL FORM OF KRAS G12D INHIBITOR AND PREPARATION METHOD THEREFOR The present disclosure relates to a crystal form of a KRAS G12D inhibitor and a preparation method therefor. Specifically, provided in the present disclosure are crystal forms A, B, C, D, E, F, G, H, I, J, K, L, M, N and O of a compound ...
WO/2024/126773A1	IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF A compound with the Formula (I): A-B-C wherein A is of the following formula (AA) and X1 is selected from O, S or NH; X2 is either N or C-H; X3 is either N or C-RA3; wherein if X1 is NH and X2 is C-H then X3 is C-RA3; B is of formula (B-...
WO/2024/127297A1	3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hyd...
WO/2024/129601A1	COMPOUND EMBODIMENTS FOR MUSCLE MYOSIN INHIBITION AND METHODS OF MAKING AND USING THE SAME Disclosed herein are compounds for use as muscle myosin inhibitors, along with methods for making and using the same. Compounds of the present disclosure can exhibit a selectivity for cardiac vs. skeletal myosin and do not inhibit non-mu...
WO/2024/129614A1	SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF Described herein are somatostatin subtype-2 receptor (SST2R) targeted thereapeutics that target tumor cells expressing SST2R and their use in the treatment of cancer.
WO/2024/127363A1	TYK2 PSEUDOKINASE LIGANDS AND USES THEREOF Described herein are compounds of formula (I) that are useful in the modulation of inflammation and treating associated disorders by acting on TYK2 to cause TYK2-mediated signal transduction inhibition. In some embodiments, the TYK2-medi...
WO/2024/126869A1	BENZOXAZINE ACETAL DERIVATIVES FOR PRODUCTION OF RECYCLABLE POLYMERS What is described is a benzoxazine derivative of the formula (I), and also a process for producing a benzoxazine derivative of the invention, and likewise a kit for production of a recyclable polymer and the use of a benzoxazine derivati...
WO/2024/130095A1	COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., for degrading certain proteins such as p300/CBP proteins).
WO/2024/125482A1	COMPOUND USED AS KETOHEXOKINASE INHIBITOR, USE THEREOF, AND COMPOSITION CONTAINING SAME Provided are a compound of formula (I), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or an isotope marker thereof, and a pharmaceutical composition containing the compound of formula (I), as well as a use of the co...
WO/2024/130173A1	BENZIMIDAZOLE DERIVATIVES Disclosed are benzimidazole derivatives, pharmaceutical compositions comprising them, and methods of using them.
WO/2024/125642A1	PYRIMIDINE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a pyrimidine-containing polycyclic derivative inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a pyrimidine-containing polycyclic compound or a s...
WO/2024/126777A1	HETEROAROMATIC COMPOUNDS The specification relates to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the tre...
WO/2024/120419A1	FUSED TETRACYCLIC COMPOUNDS AS KRAS G12D MODULATORS AND USES THEREOF This application discloses compounds of formula (I), which can be inhibitors of KRAS G12D, and their uses.
WO/2024/121184A1	INHIBITORS OF NLRP3 The invention relates to novel compounds having the general formula (I), (I) wherein R1, R2, X and W are as described herein, composition including the compounds and methods of using the compounds.
WO/2024/120433A1	FUSED CYCLIC COMPOUNDS AND USE THEREOF The invention relates to fused cyclic compounds, a composition containing the same and the use thereof.
WO/2024/119277A1	KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF The disclosure relates to KRAS inhibitor compounds having the structure of Formula (I), pharmaceutical compositions thereof, and methods of use thereof for inhibiting, treating, and/or preventing KRAS-associated diseases, disorders and c...
WO/2024/121046A1	AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS The present invention relates to compounds of formula (I) as defined in the specification capable of promoting the opening of Kv7.2/Kv7.3 potassium channels, a pharmaceutical composition comprising them, and their use as a drug, particul...

Matches 1 - 50 out of 12,168	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >